Keigo Machida, PhD

Title(s)Associate Professor of Molecular Microbiology & Immunology
Phone+1 323 442 2692
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Tokyo, School of Medicine, Tokyo, JapanPh.D.03/2001Molecular Immunology
    University of Southern California, Los Angeles, CAPost-doc05/2003Molecular Virology
    Howard Hughes Medical Institute, Los Angeles, CAPost-doc08/2005Cancer Biology
    Collapse Awards and Honors
    Japan Society for the Promotion of Science1998  - 2001Scholarship
    Asian Pacific Association for the Study of the Liver (APASL)2007Young Investigator Award
    Research Center for Liver Diseases 2007  - 2007USC Research Center for Liver Diseases Pilot Funding Award
    Liver Meeting of AASLD2008Presidential Poster of Distinction
    American Cancer Society (ACS) 2011  - 2016Research Scholar

    Collapse Overview 
    Collapse Overview
    Hepatitis C Virus (HCV) is a “silent stalker” in infected people, who can develop hepatocellular carcinomas (HCC) decades later. Our short-term goal is to study three areas:

    (i) Host-pathogen interactions to identify the mechanism of HCV-associated HCC

    (ii) Molecular virology of lymphotropic HCV in viral persistence and pathogenesis

    (iii) Cancer biology in liver oncogenesis generated from tumor-initiating cells (TICs: “bad seeds” of treatment-resistant HCC) induced by interactions between environmental factors (alcohol, obesity) and HCV.

    Our lab’s long-term goal is to test new therapeutic modalities for HCC in HCV-infected patients with alcoholism and/or obesity.

    Our experience and resources on TICs have provided a unique opportunity to functionally dissect the alcohol-mediated self-renewal of liver TICs via TLR4 signaling. The p53 tumor suppressor acts as a barrier against stem cell proliferation, and inactivation of p53, or its stabilizing partner NUMB (cell fate decision molecule), leads to expansion of TICs. Although treatment efficacy of HCV has been dramatically improved in recent years, the incidence of HCV-associated HCC keeps rising due to the prevalence of obesity, alcoholism and illicit drug usage in HCV patients. Thus, we will continue our research on the development of new therapeutic modalities for HCC.

    Collapse Research 
    Collapse Research Activities and Funding
    LncRNA with MSI2 and super-enhancer in liver cancer stem cells induced by alcohol
    NIH/NIAAA R21AA025470Sep 15, 2018 - Aug 31, 2020
    Role: Principal Investigator
    NANOG-positive cancer stem cells in liver oncogenesis induced by alcohol and HCV
    NIH/NIAAA R01AA025204Sep 1, 2017 - May 31, 2022
    Role: Principal Investigator
    Southern California Research Center for ALPD and Cirrhosis
    NIH/NIAAA P50 AA11999Jan 1, 2015 - Dec 31, 2019
    Role: Co-director of Animal Core Facility and Project 3 leader
    Role Description: This center grant supports our central research theme: elucidation of mechanisms by which alcohol sensitizes and primes the liver and pancreas for injury. Animal Core provides the intragastric ethanol infusion model to the Center members.
    Nanog-positive cancer stem cells in and liver oncogenesis by alcohol and HCV
    NIH/NIAAA R01AA018857Sep 15, 2009 - Aug 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse Featured Presentations